Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTK2 | Q05397 | 12/20 | 0.43 |
| ▸ | PTK2B | Q14289 | 11/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | GABBR2 | O75899 | 3/20 | 0.38 |
| ▸ | GABBR1 | Q9UBS5 | 3/20 | 0.38 |
| ▸ | CYP11B1 | P15538 | 3/20 | 0.37 |
| ▸ | CYP11B2 | P19099 | 3/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Formic Acid SCHEMBL30838032 | 0.95 | PTK2 (0.40) | PTK2PTK2BKCNH2CYP11B1CYP11B2 | |
| Hydrochloric Acid SCHEMBL30838010 | 0.78 | CYP11B2 (0.38) | KCNH2GABBR2GABBR1CYP11B1CYP11B2 | |
| SCHEMBL27095195 | 0.78 | TLR8 (0.40) | KCNH2CYP11B1CYP11B2 | |
| Hydrochloric Acid SCHEMBL30838057 | 0.77 | CCNT1 (0.36) | CYP11B1CYP11B2 | |
| Hydrochloric Acid SCHEMBL30838072 | 0.77 | CCNT1 (0.36) | CYP11B1CYP11B2 | |
| Hydrochloric Acid SCHEMBL30838075 | 0.77 | TLR8 (0.39) | KCNH2CYP11B1CYP11B2 | |
| SCHEMBL30838060 | 0.77 | CYP11B1 (0.41) | GABBR2GABBR1CYP11B1CYP11B2 | |
| SCHEMBL30838084 | 0.76 | CYP11B1 (0.41) | GABBR2GABBR1CYP11B1CYP11B2 | |
| SCHEMBL27142315 | 0.76 | CHEK1 (0.38) | GABBR2GABBR1CYP11B1CYP11B2 | |
| SCHEMBL27095188 | 0.76 | CHEK1 (0.38) | GABBR2GABBR1CYP11B1CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240059677-A1 | SUBSTITUTED PYRIMIDINE DERIVATIVES AS NICOTINIC ACETYLCHOLINESTERASE RECEPTOR ALPHA 6 MODULATOR | CEREVANCE LTD (GB) | 2024-02-22 | — | — | US | claimed |
| US-20240059677-A1 | SUBSTITUTED PYRIMIDINE DERIVATIVES AS NICOTINIC ACETYLCHOLINESTERASE RECEPTOR ALPHA 6 MODULATOR | CEREVANCE LTD (GB) | 2024-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240059677-A1 | SUBSTITUTED PYRIMIDINE DERIVATIVES AS NICOTINIC ACETYLCHOLINESTERASE RECEPTOR ALPHA 6 MODULATOR | CHRNA6, CHRM2, CHRNA1 | PTK2 4434/4885PTK2B 3545/4885KCNH2 1032/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.